FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Cordran Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Cordran® (flurandrenolide, USP) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
History
There is currently no drug history available for this drug.
Other Information
Cordran® (flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy, crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in ether. One gram of flurandrenolide dissolves in 72 mL of alcohol and in 10 mL of chloroform. The molecular weight of flurandrenolide is 436.52.
The chemical name of flurandrenolide is Pregn-4-ene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis (oxy)]-, (6α, 11β, 16α)-; its empirical formula is C24H33FO6. The structure is as follows:

Each gram of Cordran® Cream (flurandrenolide Cream, USP) contains 0.5 mg (1.145 µmol; 0.05%) or 0.25 mg (0.57 µmol; 0.025%) flurandrenolide in an emulsified base composed of cetyl alcohol, citric acid, mineral oil, polyoxyl 40 stearate, propylene glycol, sodium citrate, stearic acid, and purified water.
Each gram of Cordran® Ointment (flurandrenolide Ointment, USP) contains 0.5 mg (1.145 µmol; 0.05%) or 0.25 mg (0.57 µmol; 0.025%) flurandrenolide in a base composed of white wax, cetyl alcohol, sorbitan sesquioleate, and white petrolatum.
Sources
Cordran Manufacturers
- Aqua Pharmaceuticals
Cordran | Aqua Pharmaceuticals
For moist lesions, a small quantity of the cream should be rubbed gently into the affected areas 2 or 3 times a day. For dry, scaly lesions, the ointment is applied as a thin film to affected areas 2 or 3 times daily.
Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
Cordran® (flurandrenolide, USP) should not be used with occlusive dressings unless directed by a physician. Tight-fitting diapers or plastic pants may constitute occlusive dressings.
- Aqua Pharmaceuticals
Cordran | Aqua Pharmaceuticals
Shake well before using. A small quantity of Cordran Lotion should be rubbed gently into the affected area 2 or 3 times daily.
Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
Cordran Lotion should not be used with occlusive dressings unless directed by a physician. Tight-fitting diapers or plastic pants may constitute occlusive dressings.
- Actavis Pharma, Inc.
Cordran | Glaxosmithkline Llc
2.1 Important Administration Instructions • CEFTIN tablets and CEFTIN for oral suspension are not bioequivalent and are therefore not substitutable on a milligram-per-milligram basis [see Clinical Pharmacology (12.3)]. • Administer CEFTIN tablets or oral suspension as described in the appropriate dosage guidelines [see Dosage and Administration (2.2, 2.3, 2.4)]. • Administer CEFTIN tablets with or without food. • Administer CEFTIN for oral suspension with food. • Pediatric patients (aged 13 years and older) who cannot swallow the CEFTIN tablets whole should receive CEFTIN for oral suspension because the tablet has a strong, persistent bitter taste when crushed [see Dosage and Administration (2.2)]. 2.2 Dosage for CEFTIN TabletsAdminister CEFTIN tablets as described in the dosage guidelines table below with or without food.
Table 1. Adult Patients and Pediatric Patients Dosage Guidelines for CEFTIN TabletsInfection
Dosage
Duration
(Days)
Adults and Adolescents (13 years and older)
Pharyngitis/tonsillitis (mild to moderate)
250 mg every 12 hours
10
Acute bacterial maxillary sinusitis (mild to moderate)
250 mg every 12 hours
10
Acute bacterial exacerbations of chronic bronchitis (mild to moderate)
250 or 500 mg every 12 hours
10a
Secondary bacterial infections of acute bronchitis
250 or 500 mg every 12 hours
5 to 10
Uncomplicated skin and skin-structure infections
250 or 500 mg every 12 hours
10
Uncomplicated urinary tract infections
250 mg every 12 hours
7 to 10
Uncomplicated gonorrhea
1,000 mg
single dose
Early Lyme disease
500 mg every 12 hours
20
Pediatric Patients younger than 13 years (who can swallow tablets whole)b
Acute bacterial otitis media
250 mg every 12 hours
10
Acute bacterial maxillary sinusitis
250 mg every 12 hours
10
a The safety and effectiveness of CEFTIN administered for less than 10 days in patients with acute exacerbations of chronic bronchitis have not been established.
b When crushed, the tablet has a strong, persistent bitter taste. Therefore, patients who cannot swallow the tablet whole should receive the oral suspension.
2.3 Dosage for CEFTIN for Oral SuspensionAdminister CEFTIN for oral suspension as described in the dosage guidelines table below with food.
Table 2. Pediatric Patients (3 months to 12 years) Dosage Guidelines for CEFTIN for Oral SuspensionInfection
Recommended Daily Dosea Maximum Daily Dose Duration (Days)Pharyngitis/tonsillitis
20 mg/kg 500 mg10
Acute bacterial otitis media
30 mg/kg 1,000 mg10
Acute bacterial maxillary sinusitis
30 mg/kg 1,000 mg10
Impetigo
30 mg/kg 1,000 mg10
a Recommended daily dose given twice daily divided in equal doses.
2.4 Preparation and Administration of CEFTIN for Oral SuspensionPrepare a suspension at the time of dispensing as follows:
1. Shake the bottle to loosen the powder. 2. Remove the cap. 3. Add the total amount of water for reconstitution (Table 3) and replace the cap. 4. Invert the bottle and vigorously rock the bottle from side to side so that water rises through the powder. 5. Once the sound of the powder against the bottle disappears, turn the bottle upright and vigorously shake it in a diagonal direction. Table 3. Amount of Water Required for Reconstitution of Labeled Volumes of CEFTIN for Oral SuspensionOral Suspension
Amount of Water Required for Reconstitution
Labeled Volume after Reconstitution
125 mg/5 mL
37 mL
100 mL250 mg/5 mL
19 mL
50 mL35 mL
100 mL • Shake the oral suspension well before each use. • Replace cap securely after each opening. • Store the reconstituted suspension refrigerated between 2° and 8°C (36° and 46°F). • Discard the reconstituted suspension after 10 days. 2.5 Dosage in Patients with Impaired Renal FunctionA dosage interval adjustment is required for patients whose creatinine clearance is <30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney [see Clinical Pharmacology (12.3)].
Table 4. Dosing in Adults with Renal ImpairmentCreatinine Clearance (mL/min)
Recommended Dosage
≥30
No dosage adjustment
10 to ˂30
Standard individual dose given every 24 hours
˂10 (without hemodialysis)
Standard individual dose given every 48 hours
Hemodialysis
A single additional standard dose should be given at the end of each dialysis
Login To Your Free Account